A multimodal framework for assessing the link between pathomics, transcriptomics, and pancreatic cancer mutations.
Journal:
Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
Published Date:
Mar 15, 2025
Abstract
In Pancreatic Ductal Adenocarcinoma (PDAC), predicting genetic mutations directly from histopathological images using Deep Learning can provide valuable insights. The combination of several omics can provide further knowledge on mechanisms underlying tumor biology. This study aimed at developing an explainable multimodal pipeline to predict genetic mutations for the KRAS, TP53, SMAD4, and CDKN2A genes, integrating pathomic features with transcriptomics from two independent datasets, the TCGA-PAAD, assumed as training set, and the CPTAC-PDA, as external validation set. Large and small configurations of CLAM (Clustering-constrained Attention Multiple Instance Learning) models were evaluated with three different feature extractors (ResNet50, UNI, and CONCH). RNA-seq data were pre-processed both conventionally and using three autoencoder architectures. The processed transcript panels were input into machine learning (ML) models for mutation classification. Attention maps and SHAP were employed, highlighting significant features from both data modalities. A fusion layer or a voting mechanism combined the outputs from pathomic and transcriptomic models, obtaining a multimodal prediction. Performance comparisons were assessed by Area Under Receiver Operating Characteristic (AUROC) and Precision-Recall (AUPRC) curves. On the validation set, for KRAS, multimodal ML achieved 0.92 of AUROC and 0.98 of AUPRC. For TP53, the multimodal voting model achieved 0.75 of AUROC and 0.85 of AUPRC. For SMAD4 and CDKN2A, transcriptomic ML models achieved AUROC of 0.71 and 0.65, while multimodal ML showed AUPRC of 0.39 and 0.37, respectively. This approach demonstrated the potential of combining pathomics with transcriptomics, offering an interpretable framework for predicting key genetic mutations in PDAC.
